伊布替尼单药治疗经治症状性华氏巨球蛋白血症患者的长期随访
这项多中心关键试验最终分析纳入63例经治症状性华氏巨球蛋白血症患者,中位既往治疗2线,40%既往治疗难治,接受伊布替尼420 mg/d。中位随访59个月,总缓解率90.5%,主要缓解率79.4%;MYD88和CXCR4突变状态影响缓解深度、主要缓解时间及无进展生存。
要点
- 伊布替尼420 mg/d治疗经治华氏巨球蛋白血症,总缓解率90.5%,主要缓解率79.4%。
- MYD88MutCXCR4WT较MYD88MutCXCR4Mut主要缓解率更高(97.2%对68.2%)。
- ≥3级不良事件包括中性粒细胞减少15.9%、血小板减少11.1%、肺炎3.2%。
核心结论
- 伊布替尼在经治华氏巨球蛋白血症患者中具有高活性,可产生长期疾病控制,治疗可耐受;缓解深度、主要缓解时间和无进展生存受MYD88和CXCR4突变状态影响。
研究设计与样本
- 多中心关键试验的长期随访和最终分析,纳入63例经治症状性华氏巨球蛋白血症患者,中位既往治疗2线(范围1至9线),40%既往治疗难治,接受伊布替尼420 mg/d,允许因毒性减量。
主要发现
- 中位随访59个月,总缓解率90.5%,主要缓解率79.4%;最佳缓解时血清免疫球蛋白M中位值从3520 mg/dL降至821 mg/dL,骨髓疾病受累从60%降至20%,血红蛋白从10.3 g/dL升至14.2 g/dL(所有比较P < .001)。
- MYD88MutCXCR4WT患者较MYD88MutCXCR4Mut患者主要缓解率更高(97.2%对68.2%;P < .0001)、非常好的部分缓解率更高(47.2%对9.1%;P < .01)、主要缓解时间更短(1.8个月对4.7个月;P = .02)。
- 4例MYD88WT患者无主要缓解;MYD88WT患者中位无进展生存为0.4年(三组比较P < .01)。
- 所有患者5年无进展生存率未达到,MYD88MutCXCR4WT和MYD88MutCXCR4Mut患者分别为70%和38%(P = .02);所有患者5年总生存率为87%。
- 至少可能相关的≥3级不良事件在超过1例患者中包括中性粒细胞减少(15.9%)、血小板减少(11.1%)和肺炎(3.2%);8例(12.7%)发生房性心律失常,其中7例经医疗管理继续治疗。
关键数值与推荐
- 伊布替尼给药剂量为420 mg/d,允许因毒性减量。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We report the long-term findings and final analysis of a pivotal multicenter trial of ibrutinib monotherapy in previously treated patients with Waldenström macroglobulinemia (WM). PATIENTS AND METHODS: Sixty-three symptomatic patients with median prior therapies of two (range, one to nine therapies), of whom 40% were refractory to their previous therapy, received ibrutinib at 420 mg/d. Dose reduction was permitted for toxicity. RESULTS: The median follow-up was 59 months, and overall and major response rates were 90.5% and 79.4%, respectively. At best response, median serum immunoglobulin M declined from 3,520 to 821 mg/dL, bone marrow disease involvement declined from 60% to 20%, and hemoglobin rose from 10.3 to 14.2 g/dL (P < .001 for all comparisons). Responses were impacted by mutated (Mut) MYD88 and CXCR4 status. Patients with MYD88Mut, wild-type (WT) CXCR4 showed higher major (97.2% v 68.2%; P < .0001) and very good partial (47.2% v 9.1%; P < .01) response rates and a shorter time to major response (1.8 v 4.7 months; P = .02) versus patients with MYD88MutCXCR4Mut. Conversely, four patients who had MYD88WT disease showed no major responses. The median 5-year progression-free survival (PFS) rate for all patients was not reached, and was 70% and 38% for those with MYD88MutCXCR4WT and MYD88MutCXCR4Mut WM, respectively (P = .02). In patients with MYD88WT, the median PFS was 0.4 years (P < .01 for three-way comparisons). The 5-year overall survival rate for all patients was 87%. Grade ≥ 3 adverse events in more than one patient at least possibly related included neutropenia (15.9%), thrombocytopenia (11.1%), and pneumonia (3.2%). Eight patients (12.7%) experienced atrial arrhythmia, and seven of the eight continued therapy with medical management. CONCLUSION: Ibrutinib is highly active and produces long-term disease control in previously treated patients with WM. Treatment is tolerable. Response depth, time to major response, and PFS are impacted by MYD88 and CXCR4 mutation status.
引用
- Treon SP, Meid K, Gustine J, et al. Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia. J Clin Oncol. 2020. PMID: 32931398. doi:10.1200/JCO.20.00555
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。